Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold
(2021) In Journal of Medical Virology 93(3). p.1792-1795- Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the... (More)
Background: The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD have been demonstrated in clinical trials on the common cold. Method of Study: The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052). Results: CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%. Conclusion: CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission.
(Less)
- author
- Gudmundsdottir, Ágústa ; Scheving, Reynir ; Lindberg, Fredrik and Stefansson, Bjarki
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cell cultures, coronavirus, microbial cultures, respiratory tract
- in
- Journal of Medical Virology
- volume
- 93
- issue
- 3
- pages
- 1792 - 1795
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85092480286
- pmid:32975843
- ISSN
- 0146-6615
- DOI
- 10.1002/jmv.26554
- language
- English
- LU publication?
- no
- id
- 6e09b300-ad55-431e-842b-aa9ccddd8dcf
- date added to LUP
- 2021-01-08 13:13:24
- date last changed
- 2024-09-19 13:05:35
@article{6e09b300-ad55-431e-842b-aa9ccddd8dcf, abstract = {{<p>Background: The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD have been demonstrated in clinical trials on the common cold. Method of Study: The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052). Results: CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%. Conclusion: CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission.</p>}}, author = {{Gudmundsdottir, Ágústa and Scheving, Reynir and Lindberg, Fredrik and Stefansson, Bjarki}}, issn = {{0146-6615}}, keywords = {{cell cultures; coronavirus; microbial cultures; respiratory tract}}, language = {{eng}}, number = {{3}}, pages = {{1792--1795}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Journal of Medical Virology}}, title = {{Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold}}, url = {{http://dx.doi.org/10.1002/jmv.26554}}, doi = {{10.1002/jmv.26554}}, volume = {{93}}, year = {{2021}}, }